Evaluation of Cost-Utility of Varenicline Compared with Existing Smoking Cessation Therapies in South Korea
Open Access
- 1 November 2009
- journal article
- Published by Elsevier BV in Value in Health
- Vol. 12, S70-S73
- https://doi.org/10.1111/j.1524-4733.2009.00631.x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Varenicline as compared to bupropion in smoking-cessation therapy—Cost–utility results for Sweden 2003Respiratory Medicine, 2008
- Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation ModelPharmacoEconomics, 2008
- Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the NetherlandsCurrent Medical Research and Opinion, 2007
- Incidence of Chronic Obstructive Pulmonary Disease, and the Relationship between Age and Smoking in a Japanese PopulationJournal of Epidemiology, 2007
- Smoking Cessation With Varenicline, a Selective α4β2 Nicotinic Receptor Partial AgonistArchives of Internal Medicine, 2006
- Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking CessationArchives of Internal Medicine, 2006
- Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- Measuring the burden of major cancers due to smoking in KoreaCancer Science, 2006
- Smoking vs Other Risk Factors as the Cause of Smoking-Attributable DeathsJAMA, 2000